Journal
DRUGS
Volume 73, Issue 18, Pages 2017-2029Publisher
ADIS INT LTD
DOI: 10.1007/s40265-013-0146-8
Keywords
-
Categories
Funding
- Chief Scientist's Office, Scotland
- Centre for Clinical Brain Sciences, University of Edinburgh
Ask authors/readers for more resources
We review the current state of knowledge of remyelination in multiple sclerosis (MS), concentrating on advances in the understanding of the pathology and the regenerative response, and we summarise progress on the development of new therapies to enhance remyelination aimed at reducing progressive accumulation of disability in MS. We discuss key target pathways identified in experimental models, as although most identified targets have not yet progressed to the stage of being tested in human clinical trials, they may provide treatment strategies for demyelinating diseases in the future. Finally, we discuss some of the problems associated with testing this class of drugs, where they might fit into the therapeutic arsenal and the gaps in our knowledge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available